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Objective: To determine if comorbid asthma is
associated with accumulation of multiple sclerosis
(MS)-related impairment and disability.
Method: We sent a comprehensive questionnaire to a
cohort of patients with MS and examined the
association between comorbid asthma and reaching
Expanded Disability Status Scale (EDSS) scores 4.0
and 6.0. Multiple Sclerosis Impact Scale (MSIS-29)
scores were compared between patients with MS with
and without comorbid asthma.
Results: 680 patients participated in our study of
whom 88 (12.9%) had comorbid asthma. There was
no difference in the prevalence of asthma between our
MS cohort and the England general population (OR:
0.89, 95% CI 0.68 to 1.17). We did not observe a
significant association between having asthma and the
risk of reaching EDSS scores 4.0 and 6.0 (HR: 1.29,
95% CI 0.93 to 1.77, and HR: 1.33, 95% CI 0.93 to
1.89, respectively) after controlling for confounders.
Patients with MS with asthma reported higher level of
psychological impairments (coefficient: 2.29, 95% CI
0.1 to 4.49).
Conclusions: Asthma is a prevalent condition among
patients with MS and it may contribute to the
psychological impairment in MS. Although we did not
observe significant association between comorbid
asthma and physical disability in MS, it seems that the
two conditions influence one another.
INTRODUCTION
Several studies report on various aspects of
coexisting asthma and multiple sclerosis
(MS); however, the results are contradictory.
Traditionally, it was argued that the two con-
ditions are mutually exclusive: asthma is
mediated by T helper cells 2 (Th2) and MS
by Th1 cells. In 2004, an epidemiological
study from our centre found an increased
prevalence of asthma and all atopy in
patients with MS compared with the general
population.1 In contrast, a study by
Bergamaschi et al2 and another by Tremlett
and colleagues showed an inverse association
between asthma and MS. However, these
studies had lower numbers of study subjects.3
A systematic review and meta-analysis by
Monteiro et al4 has shown no evidence of an
association between asthma and MS. On the
other hand, it has been shown that patients
with MS in general bear a higher risk of
immune-mediated diseases.5–7 Apart from
the speculations on biological plausibility8
and the underlying mechanisms, the effect
of asthma on the clinical course and progno-
sis of MS has not been well understood.
In this cohort study, we compared the
general and clinical characteristics of patients
with MS with and without asthma, and inves-
tigated the association between comorbid
asthma and physical disability and psycho-
logical impairment in patients with MS.
METHOD
We analysed data from patients registered in
the Nottingham University Hospital MS
clinics. These clinics are major catchment
and referral centres in East Midlands, UK.
The centre and patient population has been
described in more detail elsewhere.9 10 In
2013, an asthma and smoking questionnaire
with questions obtained from Health Survey
Strengths and limitations of this study
▪ This is the first study investigating the associ-
ation between comorbid asthma and the progres-
sion of impairment and disability in multiple
sclerosis (MS).
▪ The data used in this study was from a well-
established cohort of patients with MS with
detailed and robust disability outcomes.
▪ Our study has a response rate of 54%. A poten-
tial selection bias may result from the proportion
of non-responders.
▪ The asthma in our study is self-reported
(although this needed to be confirmed by a
doctor).
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for England 2010, Respiratory Health (NS)11 and
European Community Respiratory Health Survey II
(ECRHS)12 were sent to 1260 patients with a definite
diagnosis of MS. Patients were eligible to participate in
the research if they were over 18 years of age and had
been diagnosed with clinically definite MS by a neurolo-
gist according to the McDonald and/or Poser cri-
teria.13 14 Patients were specifically asked if they had any
history of asthma and if so, whether this diagnosis had
been confirmed by their general practitioner (GP) or
any another relevant physician.
OUTCOMES
Through the survey, detailed data regarding any history
of asthma, individual smoking status, parental smoking
during subjects’ childhood and place of living before
the age of 5 years were obtained. The level of physical
and psychological disability were assessed by the
Multiple Sclerosis Impact Scale 29 (MSIS-29), data for
which were obtained through the questionnaire.
Data with regard to gender, age, age at the onset of
MS, duration of disease modifying treatments (DMTs),
initial clinical course of MS (relapse onset vs progressive
onset MS), and level of disability due to MS as measured
by Expanded Disability Status Scale (EDSS)15 were
obtained from the clinical database held in the Division.
The clinical database contained an average of four EDSS
scores per patient that were estimated by a neurologist
during patients’ routine clinic visits.
The study was approved by the National Research
Ethics Service East Midlands Ethics Committee Derby-1.
STATISTICAL ANALYSIS
Descriptive statistics were used to categorise the data.
Where appropriate, parametric or non-parametric two-
sided tests were employed to test the differences
between groups, and χ2 test was used to examine the dif-
ferences between categorical variables.
Association between asthma and MS
Conditional logistic regression models were used to esti-
mate the likelihood of having asthma in patients with
MS compared to the two age and sex matched controls
in England’s general population.
Risk measurement
We employed Cox proportional hazard regression
models to investigate the differences in the risk of reach-
ing two EDSS score milestones: 4.0 (walking more than
500 m unaided but having moderate disability) and 6.0
(can walk 100 m with or without assistance). The HRs
were reported as unadjusted and adjusted. Models were
adjusted for MS onset age, sex, pack years cigarette
smoked, initial clinical course of MS and exposure to
DMT. Follow-up time was started at disease onset and
ended at the time when EDSS reached the score 4.0 or
6.0 or date of last EDSS (if less than 4 or 6), whichever
occurred first; if none of those, it ended on 31
December 2013.
Median regression models were used to investigate the
association between MSIS-29 physical and psychological
scales in patients with and without asthma. The models
were adjusted for MS onset age, sex, initial clinical
course of MS, exposure to DMT and disease duration.
Only significant covariates were fitted in the final model.
All statistical analyses were performed with Stata V.13.1
(StataCorp. 2013. Stata Statistical Software: Release 13.
College Station, Texas, USA: StataCorp LP)
RESULTS
By March 2013, 680 questionnaires had been returned
by subjects who met our inclusion criteria, giving a
response rate of 54%. Mean age of respondents was 53
(SD±11.33) years with a 2:1 female:male ratio. In the
patients with MS group, 57% had relapsing remitting
MS (RR MS), 33% secondary progressive MS (SP MS),
and 10% primary progressive MS (PP MS). Mean MS
duration was 19 (SD±10.4) years and 54% were exposed
to at least 1-year of disease modifying treatments (DMTs;
table 1).
Characteristics of asthma in patients with MS
In our survey, 12.94% (n=88) of the patients reported a
history of asthma, which had been confirmed by their
GPs. When age-matched and sex-matched controls
without MS (from health survey England 2010) were
individually assigned to each MS case, we did not
observe any association between occurrence of MS and
asthma (OR: 0.89, 95% CI 0.68 to 1.17, p=0.42).
Adjustment of the model for smoking status (ever-
smoked vs never-smoked) and for parental smoking did
not change the risk of developing asthma in patients
with MS (OR: 0.92, 95% CI 0.70 to 1.23 p=0.60; detailed
analysis not shown).
Median age at the onset of asthma was 14 (range from
2 to 74) years and this onset was 5 years (95% CI 3 to 8,
p<0.001) later in people with MS compared with con-
trols without MS. Twenty eight per cent of patients with
MS with asthma reported having an attack of asthma in
the past 12 months; however, they were 40% less likely to
have an attack compared with the controls without MS
when controlled for age and sex (OR: 0.60, 95% CI 0.37
to 0.98, p=0.04).
Among patients with MS with asthma, 84% and 86%
had their first attack of asthma before MS onset and
diagnosis, respectively. Of these patients, 15.2% reported
a history of asthma in their fathers and 19.7% in their
mothers; 45.8% were receiving treatment for their
asthma. Overall, 66.6% received at least 1 year of DMTs
(median 2 years) compared with 52% of the whole
cohort of patients with MS (χ2 (1)=6.3, p=0.01).
As per place of residence, 1.1% of patients with MS
with asthma lived on a farm, 19.5% lived in a small
village, 42.5% lived in a small town, 25.3% lived in a
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suburb of a city and 11.5% lived in an inner city when
they were under the age of 5 years. For patients with MS
without asthma this was 4.5%, 24.9%, 32.1%, 31.5% and
7%, respectively (χ2(4)=8.37, p=0.08).
PRESENCE OF ASTHMA AND MS DISABILITY
Time to EDSS score milestones 4.0 and 6.0
Data needed to estimate the time to EDSS score 4.0
were available in 85% (n=581) of the patients and time
to EDSS score 6.0 in 90% (n=612) of the patients. The
proportion of missing data was not significantly different
between asthma and non-asthma groups. Total follow-up
time was 8347 and 9088 person-years for EDSS 4.0 and
for EDSS 6.0, respectively. After controlling for sex, age
at the onset of MS, disease initial clinical course,
patient’s smoking status at the time of disease onset and
exposure to DMTs, patients with MS with asthma were
not at higher risk of reaching EDSS score 4.0 or 6.0 com-
pared to those without asthma: HRs of 1.29 (95% CI
0.93 to 1.77, p=0.11) and 1.33 (95% CI 0.93 to 1.89,
p=0.11), respectively (figure 1A, B).
The unadjusted models showed almost similar results
for both EDSS 4.0 and EDSS 6.0. The magnitude was in
the same line for both EDSS scores, when the models
were adjusted for age, sex, number of pack years of
cigarettes (0–1 and more than 1 pack), DMT and MS
course (table 2).
The physical and psychological scales (MSIS-29)
We did not observe any significant association between
having asthma and overall MSIS-29 score (coefficient:
0.67, 95% CI −10.47 to 11.83, p=0.9) and MSIS-29 phys-
ical scale (coefficient: 0.41, 95% CI −7.56 to 8.39,
Table 1 General demographic and clinical characteristics of the cohort
Total (n=680) With asthma (n=88) Without asthma (n=592)
Age (mean (SD)) 53 (±11.5) 48 (±11) 53 (±11.2)
Female % 66.67 76 70
Asthma % 12.94 – –
Smoking %
Ever-smoked 62 64 62
Regularly smoked 51 48 51
Father smoked 60 55 61
Mother smoked 38 37 38
EDSS (median (IQR)) 5.5 (3 to 6.5) 4 (3 to 6.5) 5.5 (3 to 6.5)
MSIS-29 (median (IQR)) 85 (60 to 106) 84 (59 to 108) 85 (60 to 106)
Psychological scale 23 (16 to 31) 27 (17 to 34) 23 (16 to 31)
Physical scale 62 (41 to 76) 60 (42 to 77) 62 (41 to 76)
DMT (≥1-year) (%) 53 67 51
MS duration (median (IQR)) 17 (11 to 26) 16 (12 to 24) 18 (11 to 27)
Disease course (%)
Relapsing remitting 57 72 54
Secondary progressive 34 24 35
Primary progressive 9 3 10
Age at the onset of MS (median (IQR)) 33 (26 to 41) 30 (23 to 37) 33 (26 to 41)
DMT, disease-modifying treatments; EDSS, expanded disability status scale; MSIS-29, Multiple sclerosis impact scale-29; MS, multiple
sclerosis.
Figure 1 Kaplan–Meier graph showing A, time to expanded
disability status scale (EDSS) score 4.0, B, time to EDSS
score 6.0 by patients’ asthma status.
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p=0.91). However, patients with asthma had significantly
higher level of psychological impairment as measured by
MSIS-29 psychological scale (coefficient: 4.57, 95% CI
1.23 to 7.90, p=0.007; figure 2).
DISCUSSION
Here, we evaluated the association between comorbid
asthma and the clinical course of MS. As asthma is a
relatively common disease and is increasing in preva-
lence, affecting almost one in five people in countries,
such as UK,16 it seemed important to evaluate the
extent of influence of each condition on the other’s
clinical course.17 In the current work, we employed two
widely used disability outcomes in MS, EDSS and
MSIS-29. We could not find a pronounced association
between comorbid asthma and MS physical disability
although there was a trend toward a higher psycho-
logical impairment in those patients with MS who also
had asthma. We found tobacco smoking, male gender
and progressive onset to be associated with shorter time
to EDSS score milestones 4.0 and 6.0. These findings are
in line with the previously published data.18 We also
found a higher risk of reaching the two disability mile-
stones in those patients who were exposed to DMTs.
This paradoxical finding may be related to the effect of
the timing of introduction of DMT in the UK on this
clinical cohort.
Our finding of the prevalence of asthma in patients
with MS is compatible with the results from the
meta-analysis by Monteiro et al.4 However, it is different
from a previous survey in our centre and the study by
Ponsonby et al8 that showed a significantly higher preva-
lence of asthma in patients with MS;1 the results from a
survey in Wales showed reduced prevalence of asthma in
MS cases.3 The exact reason for this discrepancy needs
further investigation. The earlier study in our centre1
showed a higher proportion of people with asthma and
atopy in the MS population compared to this study.
There are several possible explanations for this. First,
the control population used in the previous work was
based on the literature and second, comparisons in the
Table 2 Risk of asthma among the cohort with MS
Crude HR (95% CI)* p Value Adjusted HR (95% CI)† p Value
Time to EDSS score 4.0 (n=605)
Asthma
No – –
Yes 1.27 (0.93 to 1.74) 0.12 1.29 (0.93 to 1.77) 0.11
Gender
Male – –
Female 0.78 (0.62 to 0.98) 0.03 0.84 (0.66 to 1.08) 0.18
Pack-years smoked from MS onset to EDSS 4.0
<1 – –
>1 1.32 (1.04 to 1.67) 0.02 1.31 (1.03 to 1.67) 0.02
DMT≥1 year
No – –
Yes 1.25 (1.00 to 1.56) 0.04 1.36 (1.07 to 1.73) 0.01
Disease clinical course at onset
Relapsing onset – –
Progressive onset 1.85 (1.34 to 2.54) <0.001 2.29 (1.62 to 3.28) <0.001
Time to EDSS score 6.0 (n=612)
Asthma
No – –
Yes 1.33 (0.93 to 1.88) 0.10 1.33 (0.93 to 1.89) 0.11
Gender
Male – –
Female 0.74 (0.58 to 0.95) 0.02 0.79 (0.61 to 1.03) 0.09
Pack-years smoked from MS onset to EDSS 6.0
<1 – –
>1 1.19 (0.92 to 1.55) 0.17 1.20 (0.91 to 1.56) 0.18
DMT ≥1 year
No – –
Yes 1.27 (1.00 to 1.62) 0.04 1.35 (1.03 to 1.76) 0.02
Disease clinical course at onset
Relapsing onset – –
Progressive onset 1.58 (1.12 to 2.21) 0.008 1.92 (1.32 to 2.78) 0.001
*The univariate cox regression models without any adjustment.
†The model was adjusted for age, sex, pack of cigarette (0 to 1 and more than 1 pack), DMTs and MS course.
DMTs, disease modifying treatments; EDSS, expanded disability status scale; MS, multiple sclerosis.
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previous work were based on prevalence in the whole
group rather than those prevalent in age and sex strati-
fied groups. Another possibility for these different
results is that the criteria used in the earlier study were
mainly based on current asthma and did not employ the
comprehensive questionnaire used in this study. As
shown here, when compared to controls without MS,
patients with asthma with MS had lower recent attack
rates (during the past 12 months) and only 45% were
receiving treatment for their asthma. Hence, use of
medication for asthma in patients with MS may be lower
than controls which may subsequently influence the
prevalence rate if prescription of a medication for
asthma was used as an identifier for asthma cases. In
addition, use of DMTs and steroids in patients with MS
should also be considered as these drugs may modify
asthma symptoms.19 20
Patients with MS are, in general, at higher risk of
other immune-mediated disease;7 however, asthma and
rheumatoid arthritis has been reported to be inversely
associated with MS.7 21 3 Most reported risk factors
common to both worsening of MS and of asthma are
stress, tobacco, having a family member with asthma (6
times higher),22 MS (2 times higher),23 and viral infec-
tions.8 Some of these risk factors have probably influ-
enced the risk of MS when the subjects were suffering
from asthma.8
Conversely, those factors which lower the risk for MS
relapses but increase asthma attacks are pregnancy, level
of physical activity and age of onset. In general, espe-
cially physical activity is lowered in MS and this can
delay the risk of asthma relapses and decrease the
asthma diagnosis in patients with MS.
Generally around the age of 20, asthma is reported to
be equally distributed between males and females;
however, in our study, the sex ratio was constantly in
favour of females. This could suggest that female hor-
mones are contributing factors to the increased risk of
developing asthma at a higher age.24
Strengths of this study include the opportunity to
examine both asthma and MS in a well-established
cohort of patients with MS with routine clinical follow-
ups and detailed information on exposure. We had
enough power to report the association between
comorbid asthma and the relevant indicators of the
course of MS. Further, this study used the self-reported
MSIS-29, which is a responsive physical and psycho-
logical scale.25
Our study has some limitations. First, the asthma in
our study is self-reported (although this needed to be
confirmed by a doctor) and our analysis is based on only
88 cases of asthma in 680 patients with MS. Hence, our
study could not be considered to be definitive. Second,
the relatively old age in our cohort (mean age 52),
which is typical for MS cohorts, may influence preva-
lence of asthma as asthma prevalence tends to decrease
with age, particularly among smokers who tend to be
diagnosed with chronic obstructive pulmonary disease
(COPD) rather than asthma.26 27 In addition, with the
response rate of 54%, a potential selection bias may
result from the proportion of non-responders among
the MS cohort.
Figure 2 A box and whisker diagram illustrate median and IQR of mean overall Multiple Sclerosis Impact Scale 29 (MSIS-29),
Physical MSIS-29 and Psychological scores.
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There has been extensive speculation regarding the
association of autoimmune and allergic diseases. The
initial hypothesis of Th1/Th2 dichotomy postulated a
deviation of the immune system towards a primarily Th1
(autoimmune) or Th2 (allergic) response, as demon-
strated by the tendency towards one or the other type of
disease in patient groups.3 28 However, the discovery of
Th17 and T regulatory (Treg) cells supports a common
pathway of disordered reactivity to self or environmental
factors, and there is evidence for Th17 and Treg
dysregulation in a wide range of autoimmune and
allergic disorders, including MS29 and asthma.30 31
Interestingly, our study shows that while the presence
of coexisting asthma has no substantial impact on the
clinical features of MS, the coexistence of MS may make
asthma milder. In addition, the majority of the patients
with MS with asthma (84%) developed asthma before
MS onset. This is compatible with the concept that the
default immune response is predominantly Th2 (as in
asthma) and in our population, most likely to precede
the MS-triggering immune response.32 Such a response
would then be disturbed and mitigated when a strong
Th1/Th17, that characterises MS, emerges despite the
extant Th2 default background.33 When considering the
results of this study, we need to take into account the
relatively low number of subjects with coexisting MS and
asthma (88 out of 680).
CONCLUSIONS
Asthma is a prevalent condition among patients with MS
and it may contribute to the psychological impairment
in MS. Although we did not observe a significant associ-
ation between comorbid asthma and physical disability
in MS, it seems that the two conditions influence one
another. The shifting toward Th1, a suggested proin-
flammatory process in MS, may play a role in the lower
risk of asthma after MS.
Contributors AM was involved in study concept and design, acquisition,
analysis and interpretation of the data and critical revision of the manuscript
for important intellectual content. CSC was involved in developing the study
concept and design, critical revision of the manuscript for important
intellectual content. CSC supervised the study and was also involved in
acquisition of data. LJE and HR were involved in interpretation of the data and
critical revision of the manuscript for important intellectual content. CRT was
involved in data analysis, interpretation of the data, design of the study and
critical revision of the manuscript for important intellectual content.
Funding This study was funded by the University of Nottingham.
Competing interests AM, CRT, HR and LJE report no disclosures. CSC has
received research support, support for travel to scientific meetings,
consultancy and speaker honoraria from Biogen Idec, Bayer-Schering,
Centocor, GW Pharmaceuticals, Merck-Serono, Morphosys and Teva
Pharmaceuticals.
Ethics approval National Research Ethics Service East Midlands Ethics
Committee Derby-1.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Edwards LJ, Constantinescu CS. A prospective study of conditions
associated with multiple sclerosis in a cohort of 658 consecutive
outpatients attending a multiple sclerosis clinic. Mult Scler
2004;10:575–81.
2. Bergamaschi R, Villani S, Crabbio M, et al. Inverse relationship
between multiple sclerosis and allergic respiratory diseases. Neurol
Sci 2009;30:115–18.
3. Tremlett HL, Evans J, Wiles CM, et al. Asthma and multiple
sclerosis: an inverse association in a case-control general practice
population. QJM 2002;95:753–6.
4. Monteiro L, Souza-Machado A, Menezes C, et al. Association
between allergies and multiple sclerosis: a systematic review and
meta-analysis. Acta Neurol Scand 2011;123:1–7.
5. Broadley SA, Deans J, Sawcer SJ, et al. Autoimmune disease in
first-degree relatives of patients with multiple sclerosis. A UK survey.
Brain 2000;123(Pt 6):1102–11.
6. Langer-Gould A, Albers KB, Van Den Eeden SK, et al. Autoimmune
diseases prior to the diagnosis of multiple sclerosis: a
population-based case-control study. Mult Scler 2010;16:855–61.
7. Roshanisefat H, Bahmanyar S, Hillert J, et al. Shared genetic factors
may not explain the raised risk of comorbid inflammatory diseases in
multiple sclerosis. Mult Scler 2012;18:1430–6.
8. Ponsonby AL, Dwyer T, van der Mei I, et al. Asthma onset prior to
multiple sclerosis and the contribution of sibling exposure in early
life. Clin Exp Immunol 2006;146:463–70.
9. Manouchehrinia A, Weston M, Tench CR, et al. Tobacco smoking
and excess mortality in multiple sclerosis: a cohort study. J Neurol
Neurosurg Psychiatry 2014;85:1091–5.
10. Manouchehrinia A, Tench CR, Maxted J, et al. Tobacco smoking
and disability progression in multiple sclerosis: United Kingdom
cohort study. Brain 2013;136(Pt 7):2298–304.
11. Centre THaSCI. Health survey for England—2010, respiratory health
[NS]. National Statistics, 2011.
12. Burney PG, Luczynska C, Chinn S, et al. The European Community
Respiratory Health Survey. Eur Respir J 1994;7:954–60.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for
multiple sclerosis: guidelines for research protocols. Ann Neurol
1983;13:227–31.
14. McDonald WI, Compston A, Edan G, et al. Recommended
diagnostic criteria for multiple sclerosis: guidelines from the
International Panel on the diagnosis of multiple sclerosis.
Ann Neurol 2001;50:121–7.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis:
an expanded disability status scale (EDSS). Neurology
1983;33:1444–52.
16. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in
England: a national study of 333,294 patients. J R Soc Med
2010;103:98–106.
17. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple
sclerosis. Lancet Neurol 2010;9:820–8.
18. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the
natural history of multiple sclerosis. Neurology 2010;74:2004–15.
19. Djukanovic ́ R, Harrison T, Johnston SL, et al. The effect of inhaled
IFN-β on worsening of asthma symptoms caused by viral infections.
A randomized trial. Am J Respir Crit Care Med 2014;190:145–54.
20. Cakebread JA, Xu Y, Grainge C, et al. Exogenous IFN-beta has
antiviral and anti-inflammatory properties in primary bronchial
epithelial cells from asthmatic subjects exposed to rhinovirus.
J Allergy Clin Immunol 2011;127:1148–54 e9.
21. Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in
patients with multiple sclerosis and their first-degree relatives: a
nationwide cohort study in Denmark. Mult Scler 2008;14:823–9.
22. Liu T, Valdez R, Yoon PW, et al. The association between family
history of asthma and the prevalence of asthma among US adults:
National Health and Nutrition Examination Survey, 1999–2004.
Genet Med 2009;11:323–8.
23. O’Gorman C, Lin R, Stankovich J, et al. Modelling genetic
susceptibility to multiple sclerosis with family data.
Neuroepidemiology 2013;40:1–12.
24. Dratva J. Use of oestrogen only hormone replacement therapy
associated with increased risk of asthma onset in postmenopausal
women. Evid Based Med 2010;15:190–1.
6 Manouchehrinia A, et al. BMJ Open 2015;5:e007806. doi:10.1136/bmjopen-2015-007806
Open Access









pen: first published as 10.1136/bm





25. Hobart JC, Riazi A, Lamping DL, et al. How responsive is the
Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with
some other self report scales. J Neurol Neurosurg Psychiatry
2005;76:1539–43.
26. Tinkelman DG, Price DB, Nordyke RJ, et al. Misdiagnosis of COPD
and asthma in primary care patients 40 years of age and over.
J Asthma 2006;43:75–80.
27. Gibson PG, Simpson JL. The overlap syndrome of asthma and
COPD: what are its features and how important is it? Thorax
2009;64:728–35.
28. Evans J, Rogers C, Wiles CM, et al. General practitioners’
prescribing data for multiple sclerosis patients indicates a link with
asthma. Br J Gen Pract 2000;50:323–4.
29. Edwards LJ, Sharrack B, Ismail A, et al. Central inflammation
versus peripheral regulation in multiple sclerosis. J Neurol
2011;258:1518–27.
30. Doe C, Bafadhel M, Siddiqui S, et al. Expression of the T helper
17-associated cytokines IL-17A and IL-17F in asthma and COPD.
Chest 2010;138:1140–7.
31. Shi YH, Shi GC, Wan HY, et al. Coexistence of Th1/Th2 and Th17/
Treg imbalances in patients with allergic asthma. Chin Med J (Engl)
2011;124:1951–6.
32. Adkins B. Development of neonatal Th1/Th2 function. Int Rev
Immunol 2000;19:157–71.
33. Edwards LJ, Robins RA, Constantinescu CS. Th17/Th1 phenotype
in demyelinating disease. Cytokine 2010;50:19–23.
Manouchehrinia A, et al. BMJ Open 2015;5:e007806. doi:10.1136/bmjopen-2015-007806 7
Open Access









pen: first published as 10.1136/bm
jopen-2015-007806 on 20 M
ay 2015. D
ow
nloaded from
 
